Literature DB >> 19551856

Active MMP-2 effectively identifies the presence of colorectal cancer.

Mary Jo Murnane1, Jinguo Cai, Sania Shuja, David McAneny, Veronica Klepeis, John B Willett.   

Abstract

Fully active MMP-2 is expressed at such low levels in human tissues that studies often fail to confirm its value as a cancer marker despite strong associations with malignancy. Our study utilized careful extraction, accurate activity measurements, standardization to purified controls and a new statistical metric to determine whether active MMP-2 is an effective indicator of colorectal cancer compared to pro-MMP-2 or pro-MMP-9. MMP-2 and MMP-9 activities were analyzed in matched normal and cancer samples from 269 patients by gelatin zymography, computer-assisted image analysis, serial dilutions of strong samples and standardization to controls. An index of effect size was designed for comparative evaluation of active MMP-2, pro-MMP-2 and pro-MMP-9 activities. For each gelatinase, mean activity and protein levels/mg soluble protein in normal mucosa and colorectal cancer were calculated for the first time with respect to commercial standards. Active MMP-2 activity, detected in 99% of colorectal cancers, was higher in 95% of cancers (on average 10-fold) than in normal mucosa. Levels of pro-MMP-2 and pro-MMP-9, but not active MMP-9, activities were also significantly higher in cancers versus normal. However, active MMP-2 activity provided the most effective test for the presence of cancer (p<0.0.0001) with an effect size statistically significantly larger than for either pro-MMP-2 or pro-MMP-9. Receiver operating characteristic (ROC) curves demonstrated that a cut-off for active MMP-2 of >44 SDU activity/mg soluble protein (>180 pg/mg), which is three times mean normal levels, would permit detection of colorectal cancer with an estimated sensitivity of 84% and estimated specificity of 93%. Copyright (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19551856      PMCID: PMC2775048          DOI: 10.1002/ijc.24682

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

Review 1.  In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections.

Authors:  S J Yan; E A G Blomme
Journal:  Vet Pathol       Date:  2003-05       Impact factor: 2.221

2.  Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa.

Authors:  S Papadopoulou; A Scorilas; N Arnogianaki; B Papapanayiotou; A Tzimogiani; N Agnantis; M Talieri
Journal:  Tumour Biol       Date:  2001 Nov-Dec

Review 3.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

4.  Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis.

Authors:  E Hrabec; M Strek; D Nowak; J Greger; M Suwalski; Z Hrabec
Journal:  J Cancer Res Clin Oncol       Date:  2002-01-22       Impact factor: 4.553

5.  Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer.

Authors:  Bor-Ching Sheu; Huang-Chun Lien; Hong-Nerng Ho; Ho-Hsiung Lin; Song-Nan Chow; Su-Cheng Huang; Su-Ming Hsu
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.

Authors:  Uta B Hofmann; Andreas A O Eggert; Katharina Blass; Eva-B Bröcker; Jürgen C Becker
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

7.  Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.

Authors:  Pao-Ling Torng; Tsui-Lien Mao; Wing-Yee Chan; Su-Cheng Huang; Chin-Tang Lin
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

8.  In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin.

Authors:  Olaf R F Mook; Claudia Van Overbeek; Eleonora G Ackema; Febe Van Maldegem; Wilma M Frederiks
Journal:  J Histochem Cytochem       Date:  2003-06       Impact factor: 2.479

9.  Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.

Authors:  E T Waas; T Wobbes; R M L M Lomme; J DeGroot; T Ruers; T Hendriks
Journal:  Br J Surg       Date:  2003-12       Impact factor: 6.939

10.  Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.

Authors:  E T Waas; R M L M Lomme; J DeGroot; Th Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  24 in total

1.  Active matrix metalloproteinase-2 activity discriminates colonic mucosa, adenomas with and without high-grade dysplasia, and cancers.

Authors:  Mary Jo Murnane; Jinguo Cai; Sania Shuja; David McAneny; John B Willett
Journal:  Hum Pathol       Date:  2011-01-15       Impact factor: 3.466

2.  CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer.

Authors:  Lin Fu; Qianze Dong; Chengyao Xie; Yan Wang; Qingchang Li
Journal:  Tumour Biol       Date:  2014-10-16

3.  Matrix-assisted refolding, purification and activity assessment using a 'form invariant' assay for matrix metalloproteinase 2 (MMP2).

Authors:  Krishna Kumar Singh; Ruchi Jain; Harini Ramanan; Deepak Kumar Saini
Journal:  Mol Biotechnol       Date:  2014-12       Impact factor: 2.695

4.  Mast cell chymase affects the proliferation and metastasis of lung carcinoma cells in vitro.

Authors:  Yuan Jiang; Yudan Wu; William James Hardie; Xiaoying Zhou
Journal:  Oncol Lett       Date:  2017-06-28       Impact factor: 2.967

Review 5.  Immunological effects and therapeutic role of C5a in cancer.

Authors:  Victoria R Darling; Ralph J Hauke; Stefano Tarantolo; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-12       Impact factor: 4.473

6.  Anticancer activity of Nelumbo nucifera stamen extract in human colon cancer HCT-116 cells in vitro.

Authors:  Xin Zhao; Xia Feng; Cun Wang; Deguang Peng; Kai Zhu; Jia-Le Song
Journal:  Oncol Lett       Date:  2016-12-28       Impact factor: 2.967

7.  Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents.

Authors:  Mohamed Nabil Abd Al Moaty; El Sayed Helmy El Ashry; Laila Fathy Awad; Nihal Ahmed Ibrahim; Marwa Muhammad Abu-Serie; Assem Barakat; Mezna Saleh Altowyan; Mohamed Teleb
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

8.  Immunoexpression of metalloproteinases 2 and 14 and TIMP-2 inhibitor in main types of primary gastric carcinomas and lymph node metastasis.

Authors:  Daniel Cordeiro Gurgel; José Telmo Valença-Junior; Conceição Aparecida Dornelas; Renato Braga Vieira; João Tarcisio Alves Maia-Filho; Roberto Cesar Pereira Lima-Junior; Ronaldo Albuquerque Ribeiro; Paulo Roberto Carvalho Almeida
Journal:  Pathol Oncol Res       Date:  2014-05-07       Impact factor: 3.201

Review 9.  MMP2 and acrosin are major proteinases associated with the inner acrosomal membrane and may cooperate in sperm penetration of the zona pellucida during fertilization.

Authors:  Marvin Ferrer; Hilma Rodriguez; Lindsay Zara; Yang Yu; Wei Xu; Richard Oko
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

Review 10.  Physiology and pathophysiology of matrix metalloproteases.

Authors:  T Klein; R Bischoff
Journal:  Amino Acids       Date:  2010-07-18       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.